ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Research Associate II at CRISPR Therapeutics - ApplyBlast

Research Associate II

CRISPR Therapeutics

25 days ago

3.1 on Glassdoor

San Francisco, California, United States

Onsite

Full Time

Medior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Research Associate II role supports the CRISPR-X team in pioneering novel gene editing therapies by building and characterizing CAR T cells generated through in-vivo gene insertion approaches. The position involves hands-on work with primary human T cells and in-vivo models to evaluate construct delivery, optimize functional assessment, and support cross-functional studies. This role sits at the intersection of immunology and next-generation gene editing to advance transformative medicines for serious human diseases.

Responsibilities

Isolate, activate, engineer, and expand primary human T cells for gene insertion studies
Design and execute CAR T cell engineering using nucleofection, viral transduction, and tLNP
Perform molecular biology workflows including cloning, PCR, and ddPCR for transgene quantification

Skills

Qualifications

BS in ImmunologyBS in BiologyBS in BioengineeringBS in GeneticsMS in Immunology

About CRISPR Therapeutics

crisprtx.com

Headquarters

Boston, Massachusetts, United States

Company Size

201-500 employees

Founded

2013

View Profile

CRISPR Therapeutics is a gene-editing company pioneering the development of transformative medicines using CRISPR/Cas9 technology to treat serious diseases. The company has a broad pipeline spanning hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo editing, and regenerative medicine, including CASGEVY™, the first-ever approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics operates across multiple clinical and preclinical programs in collaboration with partners such as Vertex Pharmaceuticals.